SCHEMBL4044640

SCHEMBL4044640

CC(C)(C)CC(N)C(=O)N1CCC2C1C(=O)CN2C(=O)Cc1cccnc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.41
CTSK P43235 2/20 0.38
TNKS O95271 1/20 0.38
PARP1 P09874 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
PARP4 Q9UKK3 1/20 0.38
PARP3 Q9Y6F1 1/20 0.38
PAX8 Q06710 1/20 0.38
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
FNTA P49354 2/20 0.35
FNTB P49356 2/20 0.35
SIGMAR1 Q99720 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRK1 P41145 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP17A1 P05093 1/20 0.33
CYP19A1 P11511 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4047662 0.89 CTSK (0.41) DPP4CTSKTNKSPARP1PARP2
SCHEMBL4039947 0.88 TNKS (0.38) DPP4CTSKTNKSPARP1PARP2
SCHEMBL4039940 0.87 PARP1 (0.39) DPP4TNKSPARP1PARP2PARP4
SCHEMBL4047936 0.85 C3AR1 (0.39) TNKSPARP1PARP2PARP4PARP3
SCHEMBL4043491 0.85 DPP4 (0.48) DPP4OPRM1
SCHEMBL4043904 0.84 DPP4 (0.44) DPP4KDM4EALDH1A1POLBMEN1
SCHEMBL4040172 0.84 DPP4 (0.43) DPP4TNKSPARP1PARP2PARP4
SCHEMBL4042039 0.83 ALDH1A1 (0.40) CTSKTNKSPARP1PARP2PARP4
SCHEMBL4039215 0.83 DPP4 (0.39) DPP4TNKSPARP1PARP2PARP4
SCHEMBL4044950 0.83 DPP4 (0.39) DPP4CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS DPP4 3448/4885CTSK 2/4885TNKS 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.